1- [4- [1- (4-Cyclohexyl-3-trifluoromethyl-benzyloxyimino) -ethyl] -2-ethyl-benzyl] -azetidine-3-carboxylic acid hemifumarate salt for use in the treatment of lymphocyte-mediated diseases
Ciszewski, Lech,De La Cruz, Marilyn,Karpinski, Piotr H.,Mutz, Michael,Riegert, Christian,Vogel, Caspar,Sschneeberger, Ricardo
申请号：
ES13177190
公开号：
ES2631203T3
申请日:
2009.12.16
申请国别(地区):
ES
年份:
2017
代理人:
摘要：
A hemifumarate salt of 1- (4- {1 - [(E) -4-cyclohexyl-3-trifluoromethyl-benzyloxyimino] -ethyl} -2-ethyl-benzyl) -azetidine-3-carboxylic acid for use in the treatment or the prevention of diseases or disorders mediated by lymphocytic interactions, in which the disease or disorder is selected from chronic or acute rejection of allografts or xenografts of cells, tissues or organs or delayed graft function, graft versus host disease； rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, myasthenia gravis, type I or II diabetes and associated disorders, vasculitis, pernicious anemia, Sjoegren's syndrome, uveitis, psoriasis, Graves ophthalmopathy, alopecia areata； allergic diseases, preferably allergic asthma, atopic dermatitis, allergic conjunctivitis / rhinitis, allergic contact dermatitis； inflammatory diseases optionally with underlying aberrant reactions, preferably inflammatory bowel disease, Crohn's disease or ulcerative colitis, intrinsic asthma, inflammatory lung injury, inflammatory liver injury, inflammatory glomerular lesion, atherosclerosis, osteoarthritis, irritative contact dermatitis and other eczematous dermatitis, seborrheic dermatitis , skin manifestations of immunologically mediated disorders, inflammatory eye disease, keratoconjunctivitis, inflammatory myopathy； myocarditis or hepatitis； ischemia / reperfusion injury, preferably myocardial infarction, stroke, intestinal ischemia, renal failure or hemorrhagic shock, traumatic shock； T-cell lymphomas or T-cell leukemia； infectious diseases, preferably toxic shock, septic shock, respiratory distress syndrome in adults or viral infections, for example AIDS, viral hepatitis, chronic bacterial infection； muscle diseases, preferably polymyositis； or senile dementia； cancer, preferably breast cancer, or as an antiangiogenic agent； peripheral neuropathies, particularly acute or chronic demyelinating neuropathies such as Guillain-Barré syndrome (GBS), chronic inflammatory demyelinating p
